Insilico Medicine has launched ALS.AI, a drug discovery platform for new amyotrophic lateral sclerosis (ALS) treatments. It uses a powerful new analytical approach involving “deep learning” to seek out new therapies for the disease — and to evaluate whether existing drugs used to treat other diseases can be repurposed for treating ALS.
Search results for:
Researchers have identified the sequence of molecular events leading to motor neuron death in amyotrophic lateral sclerosis (ALS), an important step forward that may lead to new therapies to halt this process. They found that unlike healthy astrocytes, which are…
News
Radicava’s Journey to Becoming 1st ALS Treatment in 22 Years, an Interview with MT Pharma America
Radicava, also known by its generic name edaravone, is the first treatment approved by U.S. Food and Drug Administration (FDA) in more than two decades to help amyotrophic lateral sclerosis (ALS) patients. While awaiting its arrival, ALS News Today spoke to the company responsible for its U.S. launch,…
Social Clips
What Research Is Being Done on ALS?
The National Institute of Neurological Disorders and Stroke (NINDS) is one of the world’s leading funders of research into amyotrophic lateral sclerosis (ALS). Its goals are to better understand the cellular mechanisms which lead to the development and subsequent progression of ALS, discover more about the…
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which muscles waste away due to the death of the nerve cells that control them. The condition affects limb function and produces bulbar symptoms, such as difficulty speaking and swallowing, that originate in the brainstem. The outlook for ALS…
Physicians will generally carry out a nerve conduction study (NCS) — also called a nerve conduction velocity (NCV) test — prior to ordering an electromyography (EMG) to diagnose amyotrophic lateral sclerosis (ALS). Electrical signals are passed along nerve cells throughout the body to relay messages, for example, to tell a muscle…
Mindfulness-based programs may help improve anxiety and depression in patients with amyotrophic lateral sclerosis (ALS), according to results of a study published recently in the European Journal of Neurology. The study is titled “Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trial.” The journal also published…
An imbalance between production and degradation of protein in the central nervous system may contribute to amyotrophic lateral sclerosis (ALS), researchers at England’s University of Sheffield suggest. Their study, “Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities?,” appeared in the journal Frontiers in Molecular Neuroscience. It reviewed available data showing that disturbances in…
HVH Precision Analytics presented findings of its big data analysis for earlier diagnosis of ALS (amyotrophic lateral sclerosis) to help clinicians treat patients sooner and allow patients to possibly enroll in clinical trials. HVH’s poster presentation, titled “Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS),” took place at…
Researchers at Ben-Gurion University (BGU) believe that an existing FDA-approved anti-cancer drug, rituximab, could be modified and used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In lab studies with mice, the therapy restored resident immune cells of the central nervous system, which could indicate…